NCT06575686View on ClinicalTrials.gov

Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 11, 2025

Primary Completion Date

July 16, 2028

Study Completion Date

July 16, 2028

Conditions
Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3a Follicular LymphomaRefractory Grade 1 Follicular LymphomaRefractory Grade 2 Follicular LymphomaRefractory Grade 3a Follicular Lymphoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

BIOLOGICAL

Epcoritamab

Given SC

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

DRUG

Tazemetostat

Given PO

Trial Locations (2)

91010

RECRUITING

City of Hope Medical Center, Duarte

92618

NOT_YET_RECRUITING

City of Hope at Irvine Lennar, Irvine

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER